HCW Biologics announces full exercise of pre-funded warrants by Armistice Capital

Published 01/07/2025, 13:58
HCW Biologics announces full exercise of pre-funded warrants by Armistice Capital

HCW Biologics Inc. (NASDAQ:HCWB) reported that Armistice Capital Master Fund Ltd. has fully exercised its pre-funded warrants to purchase shares of the company’s common stock. According to a press release statement in a U.S. Securities and Exchange Commission filing, Armistice exercised the remaining 54,000 pre-funded warrants on June 18, 2025.

The warrants were originally granted as part of a Securities Purchase Agreement dated May 13, 2025. They allowed Armistice to purchase up to 513,140 shares of HCW Biologics common stock at an exercise price of $0.0001 per share. Prior to June 18, Armistice had exercised warrants for a total of 459,140 shares. With the latest transaction, all pre-funded warrants under the agreement have now been exercised and none remain outstanding.

HCW Biologics is incorporated in Delaware and its principal executive offices are located in Miramar, Florida. The company’s common stock is listed on The Nasdaq Stock Market LLC under the symbol HCWB.

This information is based on a press release statement included in a recent SEC filing.

In other recent news, HCW Biologics Inc. announced the development of second-generation T-cell engagers targeting pancreatic cancer. These candidates have shown anti-cancer activity in laboratory tests and humanized mouse models. Additionally, the company has regained compliance with all Nasdaq Capital Market listing requirements, having satisfied the minimum stockholders’ equity requirement. In a significant partnership development, HCW Biologics entered a licensing agreement with WY Biotech for the novel immunotherapy molecule HCW11-006, receiving a $7.0 million upfront license fee. Furthermore, the company presented findings on HCW9206, a fusion protein that could enhance the efficacy and reduce the costs of CAR-T therapies. Despite these advancements, HCW Biologics faces legal challenges over alleged breach of contract related to its new headquarters’ construction. The lawsuit was filed by BE&K Building Group, seeking damages and costs. The company is also exploring alternative financing options to resolve financial issues linked to the construction project.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.